Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $5.81, moving 2.35% from the previous trading session.

Given that, it's hardly encouraging that Biodexa has taken a big step forward ahead of Recursion in the development of its FAP medication. The latter company's investors will be hoping that REC-4881 ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

AI-led drug for chronic lung disease set to enter phase 3 clinical trials, though experts remain divided on AI's impact in ...

According to the study, supply chain data governance is not just a technological necessity but a foundational enabler of ...

Earlier this month, venture capitalist and OpenAI backer Geoff Lewis posted an alarming video on X-formerly-Twitter, ...

Learn how to migrate PST files to Office 365 step-by-step using Microsoft tools, PowerShell, or manual upload. Secure, simple ...

Will AI take over the world? Nobody knows for sure, but we examine the most compelling arguments from both sides of the ...

From sectoral strategies to national plans, public institutions are awash in documents promising transformation: universal health care, green industrialization, and clean cooking for all by 2030. The ...